Brooks Laboratories Limited

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SUNPHARMA.NS has a market cap of 4.1T. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SUNPHARMA.NS trades at ₹1,714.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SUNPHARMA.NS's P/E ratio is 37.75. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, BROOKS.BO is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SUNPHARMA.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SUNPHARMA.BO has a market cap of 4.1T. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SUNPHARMA.BO trades at ₹1,713.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SUNPHARMA.BO's P/E ratio is 37.66. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, BROOKS.BO is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SUNPHARMA.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, DIVISLAB.NS has a market cap of 1.6T. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while DIVISLAB.NS trades at ₹5,882.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas DIVISLAB.NS's P/E ratio is 63.17. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, BROOKS.BO is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check DIVISLAB.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, DIVISLAB.BO has a market cap of 1.6T. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while DIVISLAB.BO trades at ₹5,881.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas DIVISLAB.BO's P/E ratio is 63.15. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, BROOKS.BO is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check DIVISLAB.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, TORNTPHARM.NS has a market cap of 1.4T. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while TORNTPHARM.NS trades at ₹4,029.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas TORNTPHARM.NS's P/E ratio is 60.16. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, BROOKS.BO is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check TORNTPHARM.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while TORNTPHARM.BO trades at ₹4,027.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas TORNTPHARM.BO's P/E ratio is 63.68. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, BROOKS.BO is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check TORNTPHARM.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while LUPIN.NS trades at ₹2,294.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas LUPIN.NS's P/E ratio is 22.62. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, BROOKS.BO is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check LUPIN.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while LUPIN.BO trades at ₹2,293.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas LUPIN.BO's P/E ratio is 24.30. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, BROOKS.BO is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check LUPIN.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, DRREDDY.BO has a market cap of 992B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while DRREDDY.BO trades at ₹1,191.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas DRREDDY.BO's P/E ratio is 17.56. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, BROOKS.BO is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check DRREDDY.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, DRREDDY.NS has a market cap of 992B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while DRREDDY.NS trades at ₹1,191.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas DRREDDY.NS's P/E ratio is 17.88. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, BROOKS.BO is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check DRREDDY.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ZYDUSLIFE.NS has a market cap of 897.1B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ZYDUSLIFE.NS trades at ₹891.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ZYDUSLIFE.NS's P/E ratio is 18.16. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, BROOKS.BO is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ZYDUSLIFE.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ZYDUSLIFE.BO has a market cap of 897.1B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ZYDUSLIFE.BO trades at ₹891.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ZYDUSLIFE.BO's P/E ratio is 18.16. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, BROOKS.BO is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ZYDUSLIFE.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, MANKIND.BO has a market cap of 843.1B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while MANKIND.BO trades at ₹2,042.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas MANKIND.BO's P/E ratio is 47.34. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, BROOKS.BO is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check MANKIND.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, MANKIND.NS has a market cap of 843B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while MANKIND.NS trades at ₹2,041.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas MANKIND.NS's P/E ratio is 47.30. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, BROOKS.BO is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check MANKIND.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, AUROPHARMA.NS has a market cap of 775.8B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while AUROPHARMA.NS trades at ₹1,335.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas AUROPHARMA.NS's P/E ratio is 22.24. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, BROOKS.BO is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check AUROPHARMA.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, AUROPHARMA.BO has a market cap of 775.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while AUROPHARMA.BO trades at ₹1,335.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas AUROPHARMA.BO's P/E ratio is 22.67. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, BROOKS.BO is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check AUROPHARMA.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ALKEM.BO has a market cap of 627.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ALKEM.BO trades at ₹5,246.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ALKEM.BO's P/E ratio is 26.47. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, BROOKS.BO is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ALKEM.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ALKEM.NS has a market cap of 627.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ALKEM.NS trades at ₹5,246.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ALKEM.NS's P/E ratio is 26.46. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, BROOKS.BO is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ALKEM.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, GLENMARK.BO has a market cap of 613.6B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while GLENMARK.BO trades at ₹2,174.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas GLENMARK.BO's P/E ratio is 57.72. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, BROOKS.BO is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check GLENMARK.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, GLENMARK.NS has a market cap of 613.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while GLENMARK.NS trades at ₹2,173.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas GLENMARK.NS's P/E ratio is 57.68. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, BROOKS.BO is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check GLENMARK.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, LAURUSLABS.BO has a market cap of 584.6B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while LAURUSLABS.BO trades at ₹1,082.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas LAURUSLABS.BO's P/E ratio is 69.73. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, BROOKS.BO is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check LAURUSLABS.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, LAURUSLABS.NS has a market cap of 584.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while LAURUSLABS.NS trades at ₹1,082.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas LAURUSLABS.NS's P/E ratio is 69.12. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, BROOKS.BO is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check LAURUSLABS.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, BROOKS.BO is more volatile compared to SUVENPHAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SUVENPHAR.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, BROOKS.BO is more volatile compared to SUVENPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SUVENPHAR.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, IPCALAB.BO has a market cap of 366.8B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while IPCALAB.BO trades at ₹1,445.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas IPCALAB.BO's P/E ratio is 40.37. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, BROOKS.BO is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check IPCALAB.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, IPCALAB.NS has a market cap of 366.6B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while IPCALAB.NS trades at ₹1,445.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas IPCALAB.NS's P/E ratio is 40.28. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, BROOKS.BO is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check IPCALAB.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, AJANTPHARM.BO has a market cap of 338.5B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while AJANTPHARM.BO trades at ₹2,709.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas AJANTPHARM.BO's P/E ratio is 33.41. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, BROOKS.BO is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check AJANTPHARM.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, AJANTPHARM.NS has a market cap of 338.5B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while AJANTPHARM.NS trades at ₹2,709.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas AJANTPHARM.NS's P/E ratio is 33.35. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, BROOKS.BO is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check AJANTPHARM.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, JBCHEPHARM.BO has a market cap of 312.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while JBCHEPHARM.BO trades at ₹1,945.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas JBCHEPHARM.BO's P/E ratio is 40.83. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, BROOKS.BO is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check JBCHEPHARM.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, JBCHEPHARM.NS has a market cap of 311.9B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while JBCHEPHARM.NS trades at ₹1,942.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas JBCHEPHARM.NS's P/E ratio is 40.75. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, BROOKS.BO is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check JBCHEPHARM.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, EMCURE.NS has a market cap of 296.8B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while EMCURE.NS trades at ₹1,565.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas EMCURE.NS's P/E ratio is 34.06. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to EMCURE.NS's ROE of +0.19%. Regarding short-term risk, BROOKS.BO is more volatile compared to EMCURE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check EMCURE.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, BROOKS.BO is more volatile compared to PEL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check PEL.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, WOCKPHARMA.NS has a market cap of 219.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while WOCKPHARMA.NS trades at ₹1,349.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas WOCKPHARMA.NS's P/E ratio is 1062.83. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, BROOKS.BO is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check WOCKPHARMA.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, WOCKPHARMA.BO has a market cap of 219.1B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while WOCKPHARMA.BO trades at ₹1,348.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas WOCKPHARMA.BO's P/E ratio is 1061.57. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, BROOKS.BO is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check WOCKPHARMA.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, NATCOPHARM.NS has a market cap of 199.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while NATCOPHARM.NS trades at ₹1,112.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas NATCOPHARM.NS's P/E ratio is 12.80. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, BROOKS.BO is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check NATCOPHARM.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, NATCOPHARM.BO has a market cap of 199.1B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while NATCOPHARM.BO trades at ₹1,111.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas NATCOPHARM.BO's P/E ratio is 12.94. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, BROOKS.BO is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check NATCOPHARM.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ASTRAZEN.BO has a market cap of 197.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ASTRAZEN.BO trades at ₹7,890.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ASTRAZEN.BO's P/E ratio is 98.00. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, BROOKS.BO is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ASTRAZEN.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ASTRAZEN.NS has a market cap of 197.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ASTRAZEN.NS trades at ₹7,889.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ASTRAZEN.NS's P/E ratio is 97.86. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, BROOKS.BO is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ASTRAZEN.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, PPLPHARMA.BO has a market cap of 190.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while PPLPHARMA.BO trades at ₹143.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas PPLPHARMA.BO's P/E ratio is -116.05. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, BROOKS.BO is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check PPLPHARMA.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ERIS.NS has a market cap of 187B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ERIS.NS trades at ₹1,350.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ERIS.NS's P/E ratio is 42.86. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, BROOKS.BO is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ERIS.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ERIS.BO has a market cap of 187B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ERIS.BO trades at ₹1,349.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ERIS.BO's P/E ratio is 42.81. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, BROOKS.BO is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ERIS.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, NEULANDLAB.NS has a market cap of 180.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while NEULANDLAB.NS trades at ₹14,055.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas NEULANDLAB.NS's P/E ratio is 100.93. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, BROOKS.BO is more volatile compared to NEULANDLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check NEULANDLAB.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, NEULANDLAB.BO has a market cap of 180.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while NEULANDLAB.BO trades at ₹14,050.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas NEULANDLAB.BO's P/E ratio is 100.89. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, BROOKS.BO is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check NEULANDLAB.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, GRANULES.BO has a market cap of 156.6B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while GRANULES.BO trades at ₹645.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas GRANULES.BO's P/E ratio is 28.69. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, BROOKS.BO is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check GRANULES.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, GRANULES.NS has a market cap of 156.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while GRANULES.NS trades at ₹644.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas GRANULES.NS's P/E ratio is 28.66. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, BROOKS.BO is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check GRANULES.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, APLLTD.BO has a market cap of 143.5B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while APLLTD.BO trades at ₹729.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas APLLTD.BO's P/E ratio is 22.75. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, BROOKS.BO is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check APLLTD.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, APLLTD.NS has a market cap of 142.8B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while APLLTD.NS trades at ₹726.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas APLLTD.NS's P/E ratio is 22.63. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, BROOKS.BO is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check APLLTD.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, JUBLPHARMA.NS has a market cap of 139B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while JUBLPHARMA.NS trades at ₹877.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas JUBLPHARMA.NS's P/E ratio is 32.26. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, BROOKS.BO is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check JUBLPHARMA.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, JUBLPHARMA.BO has a market cap of 139B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while JUBLPHARMA.BO trades at ₹877.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas JUBLPHARMA.BO's P/E ratio is 32.26. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, BROOKS.BO is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check JUBLPHARMA.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, BROOKS.BO is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check GLS.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, BROOKS.BO is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check GLS.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ALIVUS.NS has a market cap of 128.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ALIVUS.NS trades at ₹1,044.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ALIVUS.NS's P/E ratio is 23.60. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, BROOKS.BO is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ALIVUS.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ALIVUS.BO has a market cap of 128B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ALIVUS.BO trades at ₹1,043.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ALIVUS.BO's P/E ratio is 23.58. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, BROOKS.BO is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ALIVUS.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, CAPLIPOINT.NS has a market cap of 126.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while CAPLIPOINT.NS trades at ₹1,660.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas CAPLIPOINT.NS's P/E ratio is 20.63. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, BROOKS.BO is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check CAPLIPOINT.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, CAPLIPOINT.BO has a market cap of 126.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while CAPLIPOINT.BO trades at ₹1,660.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas CAPLIPOINT.BO's P/E ratio is 20.64. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, BROOKS.BO is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check CAPLIPOINT.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, COHANCE.NS has a market cap of 118.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while COHANCE.NS trades at ₹309.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas COHANCE.NS's P/E ratio is 61.05. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, BROOKS.BO is more volatile compared to COHANCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check COHANCE.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, COHANCE.BO has a market cap of 118.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while COHANCE.BO trades at ₹309.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas COHANCE.BO's P/E ratio is 61.02. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, BROOKS.BO is more volatile compared to COHANCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check COHANCE.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, BROOKS.BO is more volatile compared to CAPPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check CAPPL.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, VIYASH.NS has a market cap of 90.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while VIYASH.NS trades at ₹206.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas VIYASH.NS's P/E ratio is 79.57. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, BROOKS.BO is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check VIYASH.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, STAR.BO has a market cap of 89.1B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while STAR.BO trades at ₹967.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas STAR.BO's P/E ratio is 17.43. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, BROOKS.BO is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check STAR.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, STAR.NS has a market cap of 88.9B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while STAR.NS trades at ₹964.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas STAR.NS's P/E ratio is 17.39. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, BROOKS.BO is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check STAR.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, PGHL.NS has a market cap of 80.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while PGHL.NS trades at ₹4,843.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas PGHL.NS's P/E ratio is 34.01. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, BROOKS.BO is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check PGHL.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, PGHL.BO has a market cap of 80.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while PGHL.BO trades at ₹4,837.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas PGHL.BO's P/E ratio is 33.91. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, BROOKS.BO is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check PGHL.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SHILPAMED.NS has a market cap of 79B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SHILPAMED.NS trades at ₹403.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SHILPAMED.NS's P/E ratio is 35.69. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, BROOKS.BO is more volatile compared to SHILPAMED.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SHILPAMED.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, AKUMS.NS has a market cap of 77.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while AKUMS.NS trades at ₹504.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas AKUMS.NS's P/E ratio is 24.15. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to AKUMS.NS's ROE of +0.10%. Regarding short-term risk, BROOKS.BO is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check AKUMS.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SUDEEPPHRM.NS has a market cap of 69.6B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SUDEEPPHRM.NS trades at ₹616.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SUDEEPPHRM.NS's P/E ratio is 41.32. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, BROOKS.BO is more volatile compared to SUDEEPPHRM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SUDEEPPHRM.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, AARTIPHARM.NS has a market cap of 62.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while AARTIPHARM.NS trades at ₹688.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas AARTIPHARM.NS's P/E ratio is 29.18. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, BROOKS.BO is more volatile compared to AARTIPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check AARTIPHARM.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, AARTIPHARM.BO has a market cap of 62.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while AARTIPHARM.BO trades at ₹686.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas AARTIPHARM.BO's P/E ratio is 29.14. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, BROOKS.BO is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check AARTIPHARM.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, FDC.BO has a market cap of 56.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while FDC.BO trades at ₹346.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas FDC.BO's P/E ratio is 26.05. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, BROOKS.BO is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check FDC.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, FDC.NS has a market cap of 56.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while FDC.NS trades at ₹345.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas FDC.NS's P/E ratio is 26.00. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, BROOKS.BO is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check FDC.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, BROOKS.BO is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SEQUENT.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, BROOKS.BO is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SEQUENT.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SPARC.BO has a market cap of 44.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SPARC.BO trades at ₹136.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SPARC.BO's P/E ratio is -16.51. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, BROOKS.BO is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SPARC.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SPARC.NS has a market cap of 44.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SPARC.NS trades at ₹136.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SPARC.NS's P/E ratio is -16.50. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, BROOKS.BO is more volatile compared to SPARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SPARC.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SHILPAMED.BO has a market cap of 39.4B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SHILPAMED.BO trades at ₹402.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SHILPAMED.BO's P/E ratio is 35.57. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, BROOKS.BO is more volatile compared to SHILPAMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SHILPAMED.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SUVEN.NS has a market cap of 39.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SUVEN.NS trades at ₹169.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SUVEN.NS's P/E ratio is -13.72. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, BROOKS.BO is more volatile compared to SUVEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SUVEN.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SUVEN.BO has a market cap of 39.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SUVEN.BO trades at ₹169.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SUVEN.BO's P/E ratio is -13.73. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, BROOKS.BO is more volatile compared to SUVEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SUVEN.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, INNOVACAP.NS has a market cap of 39.1B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while INNOVACAP.NS trades at ₹683.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas INNOVACAP.NS's P/E ratio is 29.50. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, BROOKS.BO is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check INNOVACAP.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, AARTIDRUGS.NS has a market cap of 33B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while AARTIDRUGS.NS trades at ₹361.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas AARTIDRUGS.NS's P/E ratio is 16.35. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, BROOKS.BO is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check AARTIDRUGS.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, AARTIDRUGS.BO has a market cap of 33B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while AARTIDRUGS.BO trades at ₹361.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas AARTIDRUGS.BO's P/E ratio is 16.33. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, BROOKS.BO is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check AARTIDRUGS.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, RPGLIFE.BO has a market cap of 31.1B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while RPGLIFE.BO trades at ₹1,883.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas RPGLIFE.BO's P/E ratio is 15.36. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, BROOKS.BO is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check RPGLIFE.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, RPGLIFE.NS has a market cap of 31B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while RPGLIFE.NS trades at ₹1,872.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas RPGLIFE.NS's P/E ratio is 15.28. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, BROOKS.BO is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check RPGLIFE.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, GUJTHEM.NS has a market cap of 30.7B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while GUJTHEM.NS trades at ₹282.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas GUJTHEM.NS's P/E ratio is 64.12. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, BROOKS.BO is more volatile compared to GUJTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check GUJTHEM.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, GUFICBIO.BO has a market cap of 30.1B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while GUFICBIO.BO trades at ₹300.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas GUFICBIO.BO's P/E ratio is 60.34. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, BROOKS.BO is more volatile compared to GUFICBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check GUFICBIO.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, GUFICBIO.NS has a market cap of 30B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while GUFICBIO.NS trades at ₹299.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas GUFICBIO.NS's P/E ratio is 59.98. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, BROOKS.BO is more volatile compared to GUFICBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check GUFICBIO.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ORCHPHARMA.NS has a market cap of 27.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ORCHPHARMA.NS trades at ₹537.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ORCHPHARMA.NS's P/E ratio is 143.78. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, BROOKS.BO is more volatile compared to ORCHPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ORCHPHARMA.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ORCHPHARMA.BO has a market cap of 27.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ORCHPHARMA.BO trades at ₹537.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ORCHPHARMA.BO's P/E ratio is 143.32. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, BROOKS.BO is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ORCHPHARMA.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, BLISSGVS.BO has a market cap of 26.7B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while BLISSGVS.BO trades at ₹252.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas BLISSGVS.BO's P/E ratio is 24.82. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, BROOKS.BO is more volatile compared to BLISSGVS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check BLISSGVS.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, BLISSGVS.NS has a market cap of 26.7B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while BLISSGVS.NS trades at ₹252.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas BLISSGVS.NS's P/E ratio is 24.83. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, BROOKS.BO is more volatile compared to BLISSGVS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check BLISSGVS.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, NOVARTIND.BO has a market cap of 24.7B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while NOVARTIND.BO trades at ₹1,001.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas NOVARTIND.BO's P/E ratio is 25.38. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, BROOKS.BO is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check NOVARTIND.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, IOLCP.NS has a market cap of 23.6B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while IOLCP.NS trades at ₹80.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas IOLCP.NS's P/E ratio is 20.39. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, BROOKS.BO is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check IOLCP.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, IOLCP.BO has a market cap of 23.6B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while IOLCP.BO trades at ₹80.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas IOLCP.BO's P/E ratio is 20.39. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, BROOKS.BO is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check IOLCP.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SOLARA.NS has a market cap of 23.3B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SOLARA.NS trades at ₹483.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SOLARA.NS's P/E ratio is -100.46. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, BROOKS.BO is more volatile compared to SOLARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SOLARA.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, UNICHEMLAB.BO has a market cap of 23.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while UNICHEMLAB.BO trades at ₹329.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas UNICHEMLAB.BO's P/E ratio is 7.89. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, BROOKS.BO is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check UNICHEMLAB.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, UNICHEMLAB.NS has a market cap of 23.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while UNICHEMLAB.NS trades at ₹329.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas UNICHEMLAB.NS's P/E ratio is 7.88. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, BROOKS.BO is more volatile compared to UNICHEMLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check UNICHEMLAB.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, SOLARA.BO has a market cap of 23.2B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while SOLARA.BO trades at ₹480.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas SOLARA.BO's P/E ratio is -100.20. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, BROOKS.BO is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check SOLARA.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, MOREPENLAB.NS has a market cap of 22B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while MOREPENLAB.NS trades at ₹40.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas MOREPENLAB.NS's P/E ratio is 22.33. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to MOREPENLAB.NS's ROE of +0.09%. Regarding short-term risk, BROOKS.BO is more volatile compared to MOREPENLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check MOREPENLAB.NS's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, MOREPENLAB.BO has a market cap of 22B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while MOREPENLAB.BO trades at ₹40.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas MOREPENLAB.BO's P/E ratio is 22.44. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, BROOKS.BO is more volatile compared to MOREPENLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check MOREPENLAB.BO's competition here

BROOKS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BROOKS.BO stands at 2.1B. In comparison, ALEMBICLTD.NS has a market cap of 22B. Regarding current trading prices, BROOKS.BO is priced at ₹71.49, while ALEMBICLTD.NS trades at ₹85.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BROOKS.BO currently has a P/E ratio of 9.73, whereas ALEMBICLTD.NS's P/E ratio is 6.89. In terms of profitability, BROOKS.BO's ROE is +0.23%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, BROOKS.BO is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BROOKS.BO.Check ALEMBICLTD.NS's competition here